Details

Details

Title Randomized Phase 2 Four Arm Study In Patients 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation; Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation; Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation; Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation

IRB ECOG 1411

CC 12-690

Hospital Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster

Phase Phase 2

Disease Lymphoma, Lymphoma, Mantle Cell, Lymphoma, Non - Hodgkin

Drug Bendamustine , Bortezomib , Lenalidomide (Revlimid), Rituximab

Description

Description

Inclusion Criteria

Inclusion Criteria

Exclusion Criteria

Exclusion Criteria